← brief for 2026-09-08 · Slowing decline

Sodium-glucose cotransporter-2 inhibitors, severe sepsis, and infection-related outcomes in patients with chronic kidney disease and type 2 diabetes.

Article C Peer reviewed Observational

Key takeaways

SGLT2 inhibitors are a common drug class that protects the kidneys and heart in people with diabetes. This study asked a different question: do they raise or lower the risk of severe blood infection (sepsis) in people who have both chronic kidney disease and type 2 diabetes? Researchers followed new users of these drugs in a large U.S. health records database and compared them with people starting a different drug. Because nobody was assigned a drug at random, this can show a link only, not proof of cause, and the abstract does not report the final numbers.

Who did this work

Wang CA · Wang WJ · Chen JY · Tseng YH · Cheng CY · Wu VC

Source

Article · PubMed, the drug frontier · 2026 Sep 9
https://pubmed.ncbi.nlm.nih.gov/42711252/